Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC By Ogkologos - September 7, 2026 8 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-671 study after 5 years of follow-up Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... MOST POPULAR FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway... July 15, 2026 Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... July 25, 2023 Molecular Burglary: Cancer Cells Hijack Energy from Immune Cells November 21, 2023 FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma June 2, 2021 Load more HOT NEWS 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... An Oncology Hospital at Home Model of Acute Care Shows Promise EMA Recommends Granting a Marketing Authorisation for Nirogacestat What to Know About Getting Access to New Cancer Advances Presented...
